Top Page
IVD Medical Holding Limited
(1931)
IVD Medical Holding Limited (1931) vs. iShares MSCI Hong Kong ETF (EWH)
IVD Medical Holding Limited Business Overview & Revenue Model
IVD Medical Holding Limited Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.08B | 3.16B | 3.09B | 2.75B | 2.73B | 2.43B |
| Gross Profit | 706.08M | 751.17M | 671.70M | 608.14M | 566.27M | 476.17M |
| EBITDA | 401.57M | 475.96M | 397.93M | 349.66M | 286.17M | 250.04M |
| Net Income | 174.25M | 260.42M | 238.16M | 210.00M | 174.54M | 158.72M |
Balance Sheet | ||||||
| Total Assets | 6.16B | 5.52B | 4.79B | 4.31B | 4.37B | 3.91B |
| Cash, Cash Equivalents and Short-Term Investments | 427.55M | 1.86B | 1.24B | 1.04B | 841.78M | 794.74M |
| Total Debt | 1.67B | 755.97M | 344.32M | 349.92M | 427.65M | 421.80M |
| Total Liabilities | 2.63B | 1.76B | 1.40B | 1.16B | 1.37B | 1.05B |
| Stockholders Equity | 3.47B | 3.71B | 3.34B | 3.15B | 2.98B | 2.85B |
Cash Flow | ||||||
| Free Cash Flow | 99.21M | 88.69M | 251.92M | 215.39M | 137.88M | 144.87M |
| Operating Cash Flow | 136.55M | 140.29M | 292.42M | 249.67M | 163.11M | 170.49M |
| Investing Cash Flow | -2.00M | -57.80M | -77.58M | 60.54M | -27.88M | -196.00M |
| Financing Cash Flow | -18.46M | 395.13M | -19.45M | -191.29M | -66.29M | -63.24M |
IVD Medical Holding Limited Technical Analysis
IVD Medical Holding Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.50B | 15.96 | 6.72% | 2.72% | 29.81% | 10.40% | |
72 Outperform | HK$65.97B | 3.78 | 8.54% | 3.75% | -2.68% | -21.45% | |
66 Neutral | HK$1.95B | 20.84 | 4.85% | 3.81% | 0.33% | -44.28% | |
64 Neutral | HK$65.16B | 15.13 | 7.64% | 2.67% | 2.77% | 39.24% | |
60 Neutral | HK$626.40M | 7.99 | 7.98% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$418.23M | -0.52 | -78.61% | ― | -43.86% | -217.25% |
IVD Medical Holding Limited Corporate Events
ETHK Labs Inc. has announced that its subsidiary Shenzhen ICXIVD Biotechnology has successfully developed a dual-platform solution for Nipah virus detection, addressing an urgent global need for rapid, accurate diagnostics amid a recent Nipah outbreak in India and the broader threat posed by high-fatality zoonotic viruses without existing specific treatments. The new solution, built on ICXIVD’s proprietary AI primer design platform and species-specific nucleic acid database, includes a Nipah Virus Nucleic Acid Detection Kit (Fluorescent PCR Method) that is compatible with mainstream PCR equipment, delivers results within an hour, supports flexible throughput configurations and aims to enhance the reliability, speed and scalability of public health emergency responses while advancing the group’s AI healthcare strategy and positioning in molecular diagnostics.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
ETHK Labs Inc. has formally changed its English corporate name from IVD Medical Holding Limited to ETHK Labs Inc., while retaining its existing Chinese name, following shareholder approval at an extraordinary general meeting and subsequent regulatory confirmation in both the Cayman Islands and Hong Kong. The company will also update its English stock short name on the Hong Kong Stock Exchange from “IVD MEDICAL” to “ETHK LABS INC.” with effect from 30 January 2026, while its Chinese stock short name and stock code 1931 remain unchanged; the name change will not affect shareholders’ rights, daily operations or the company’s financial position, and existing share certificates will remain valid with no exchange arrangement required, signaling a rebranding rather than a change in underlying business fundamentals.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
ETHK Labs Inc. has announced substantial changes to its leadership and governance structure effective 13 January 2026, with the resignation of executive directors Mr. Law Kim Fai and Ms. Tai Yang, and independent non-executive director Mr. Wong Sze Lok, alongside Mr. Law stepping down as chief financial officer, company secretary and authorised representative. In response, the company has reshuffled key board committees, appointing Mr. Zhang Jianlei as chairman of both the audit and remuneration committees, adding Mr. Chan Siu Kei Ken to the nomination committee and naming him company secretary, and appointing Mr. Zhong Renqian and Mr. Xu Da to the remuneration committee. The changes leave the nomination committee temporarily without gender diversity as required under Hong Kong’s corporate governance code, and the board has indicated it will review the committee’s composition, underscoring ongoing governance obligations and the importance of maintaining regulatory compliance amid senior management turnover.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
ETHK Labs Inc. has announced the current composition of its board of directors and the allocation of roles across key board committees, formalizing its governance framework for investors and stakeholders. The board consists of two executive directors, two non-executive directors and three independent non-executive directors, with independent director Zhang Jianlei appointed as chairman of the audit, remuneration and nomination committees, and other independent directors serving as members, underscoring an emphasis on independent oversight and alignment with corporate governance best practices in the Hong Kong market.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited announced that during its extraordinary general meeting held on November 26, 2025, a special resolution to change the company’s English name was passed with unanimous support. This decision reflects a strategic move that could impact the company’s brand identity and market positioning, potentially influencing stakeholder perceptions and future business operations.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced its acquisition of a significant stake in B-Soft Co., Ltd, a move that positions the company to hold approximately 12.64% of the voting rights in B-Soft. This strategic acquisition, valued at RMB500 million, involves the purchase of 96,525,096 A shares, representing 6.23% of B-Soft’s total issued share capital. Additionally, the company has secured voting rights for an additional 195,780,282 A shares through agreements with the vendor and a private fund. This transaction is classified as a discloseable transaction under Chapter 14 of the Listing Rules, requiring reporting and announcement but exempt from shareholder approval. The acquisition is contingent on regulatory approvals and other conditions, and stakeholders are advised to exercise caution.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced that it is in discussions to potentially acquire control over B-Soft Co., Ltd., a company listed on the ChiNext Board of the Shenzhen Stock Exchange. The transaction, if completed, could significantly impact IVD Medical’s market positioning by expanding its influence in the Chinese market. However, the transaction is still under negotiation, and there are various conditions and approvals required before it can proceed. Shareholders are advised to exercise caution as the deal may not materialize.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.
IVD Medical Holding Limited has announced an extraordinary general meeting scheduled for November 26, 2025, to consider a special resolution for changing its English name to ETHK Labs Inc. This change, pending approval from the Cayman Islands Registrar of Companies, signifies a strategic rebranding effort that could impact the company’s market positioning and stakeholder perception.
The most recent analyst rating on (HK:1931) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.